trending Market Intelligence /marketintelligence/en/news-insights/trending/JIEc6fNXjMvkZXP5BwRZWA2 content esgSubNav
In This List

Foamix, LEO Pharma settle patent dispute with Teva over Finacea topical foam

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Foamix, LEO Pharma settle patent dispute with Teva over Finacea topical foam

Foamix Pharmaceuticals Ltd. and LEO Pharma A/S settled a patent litigation with Petah Tikva, Israel-based Teva Pharmaceutical Industries Ltd. regarding Finacea foam, a topical treatment for a chronic skin disease.

Foamix did not disclose terms of the settlement agreement, which is is subject to the review of the U.S. Federal Trade Commission and the U.S. Department of Justice.

Foamix granted Ballerup, Denmark-based Leo Pharma a license to market Finacea foam, whose active ingredient is azelaic acid. Finacea treats inflammatory papules, or raised spots, and pimple-like bumps caused by rosacea — a common condition that causes persistent redness over the face and nose.

In April, Rehovot, Israel-based Foamix settled a patent dispute regarding Finacea with Perrigo Co. PLC, a Dublin-based maker of generic drugs. Foamix said it will pursue patent infringement litigation involving Finacea against Taro Pharmaceutical Industries Ltd. and its U.S. unit.